Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MESA
- Development stage
- Unknown
- Lead developer
- Xijing Hospital
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Intramuscular, Intravenous
01
Overview
**MESA** is a multi-agent antineoplastic chemotherapy regimen comprising methotrexate, etoposide, dexamethasone, and pegaspargase, a pegylated L-asparaginase. It has been studied with radiotherapy for early-stage extranodal natural killer/T-cell lymphoma, nasal type. Methotrexate inhibits dihydrofolate reductase and folate-dependent nucleotide synthesis; etoposide poisons DNA topoisomerase II; dexamethasone activates the glucocorticoid receptor; and pegaspargase depletes circulating L-asparagine, exploiting lymphoma-cell dependence on extracellular asparagine. ([chictr.org.cn](https://www.chictr.org.cn/showproj.html?proj=4387))
- Other names
- MESA chemotherapy regimenmethotrexate + etoposide + dexamethasone + pegaspargase
02
Targets
TOP2B (DNA topoisomerase II beta)ATIC (Aminoimidazole carboxamide ribonucleotide transformylase)TS (Thymidylate synthase)DHFR (Dihydrofolate reductase)TOP2A (DNA topoisomerase II)GR (Glucocorticoid receptor)MR (Mineralocorticoid receptor)
Beyond the preview
Go deeper on MESA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MESA.